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Diabetes mellitus (DM) is an important risk factor for adverse outcomes of coronary artery bypass
grafting. The bypass grafts harvested from patients with DM tend to go into spasm after their im-
plantation into the coronary circulation. To clarify the contribution of 5-hydroxytriptamine (5-HT) and
angiotensin II (AngII) in the bypass graft spasm, we examined the contractile reactivity to 5-HT or AngII
of isolated human endothelium-denuded saphenous vein (SV) harvested from DM and non-DM patients.
The 5-HT-induced constriction of the SV was signiﬁcantly augmented in the DM group than in the non-
DM group, which is similar to our previous report. AngII-induced constriction of the SV was also sig-
niﬁcantly augmented in the DM group than the non-DM group. Especially in the non-DM group, the
AngII-induced maximal vasoconstriction was markedly lower than the 5-HT-induced one. Meanwhile,
the increasing rates of AngII-induced vasoconstriction in the DM group to the non-DM group were
signiﬁcantly greater than those of 5-HT-induced vasoconstriction. These results indicate that 5-HT is a
potent inducer of SV graft spasm in both DM and non-DM patients, while AngII is a potent inducer of SV
graft spasm only in patients with DM. Furthermore, the protein level of AngII AT1 receptor (AT1R), but not
the protein level of 5-HT2A receptor, in the membrane fraction of the SV smooth muscle cells of DM
patients was signiﬁcantly increased as compared with that of the non-DM patients. These results suggest
that the mechanism for hyperreactivity to AngII in the SV from DM patients is due to, at least in part, the
increase in the amount of AT1R on membrane of the SV smooth muscle cells.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery bypass grafting (CABG) remains the gold
standard therapy for severe coronary artery disease involving
three-vessel or left main coronary disease [1]. Especially among
patients with diabetes mellitus (DM), CABG has a better prognosis
than percutaneous coronary intervention [1,2]. However, DM is an
established risk factor for early and late adverse outcomes after
CABG [3], with the most serious associated complication being the
spasm of bypass grafts after their implantation into the coronary
circulation, which can lead to premature occlusion and increasedB.V. This is an open access article u
amoto).perioperative morbidity [4,5]. The saphenous vein (SV) has been
widely used as a conduit for CABG because of its ready availability
and suppleness [6]. We previously reported that the constrictive
responses induced by 5-hydroxytryptamine (5-HT) in the human
endothelium-denuded SVs isolated from patients with DM were
signiﬁcantly augmented compared with those in veins isolated
from patients without DM (non-DM) [7]. Based on these results,
we hypothesized that increased reactivity to 5-HT may be re-
sponsible for vasospasm after CABG among diabetic patients.
Insulin resistance, a well-known risk factor for type 2 DM,
upregulates the renin-angiotensin-aldosterone system (RAAS),
which is involved in the pathogenesis of hypertension, arterio-
sclerosis, and ischemic heart failure [8,9]. Angiotensin II (AngII) is
part of the RAAS and plays important roles in regulating thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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AngII acts primarily through the angiotensin AT1 receptor (AT1R)
to exert the most of its biological effects, including the constriction
of vascular smooth muscle. AngII-induced constrictive responses
of the SVs harvested from DM patients may be augmented in a
similar manner to 5-HT-induced responses, because AT1R, like the
5-HT2A receptor, is a Gq-coupled receptor. However, little is known
about the inﬂuence of DM on AngII-induced vasoconstriction of
human SVs. Hence, we examined the effect of DM on AngII-in-
duced vasoconstriction, in comparison to 5-HT-induced vasocon-
striction, of endothelium-denuded SV grafts harvested from both
DM and non-DM patients. We further determined the levels of
5-HT2A receptor and AT1R on the SV smooth muscle membrane.2. Materials and methods
2.1. Preparation of blood vessels and contractile studies
The human SVs were obtained from patients undergoing CABG
at Miyazaki Prefectural Nobeoka Hospital (Nobeoka, Japan) or
surgical varicose vein treatment at Kuwabara Clinic (Miyazaki,
Japan). SV samples from 15 patients with DM (DM group) and 25
patients without DM (non-DM group) were used in this study. The
diabetes status of patients was accepted as diagnosed from the
medical records. The hemoglobin A1c (HbA1c) levels of the DM
group were 6.670.1 (only 7 DM patients who were conﬁrmed by
us). We could not follow the HbA1c data of the other DM patients
or non-DM patients. At Miyazaki Prefectural Nobeoka Hospital,
portions of each great SV graft were sectioned to the desired
lengths for bypassing the occluded coronary arteries, while the
remainder was used for the experiments. At Kuwabara Clinic,
portions of the SV were sectioned from each patient as a surgical
treatment for varix of the lower extremity, and only the non-dis-
tended areas were used for the experiments. The small SV seg-
ments were transported and their constrictive responses were
measured as described previously [11,12]. In brief, isolated vessels
were placed in modiﬁed Krebs buffer, which had been previously
aerated with 95% O2 and 5% CO2, and transported promptly to our
laboratory. The composition of modiﬁed Krebs buffer solution was
as follows: 118.0 mM NaCl, 4.7 mM KC1, 25.0 mM NaHCO3, 1.2 mM
MgSO4, 1.1 mM KH2PO4, 2.5 mM CaCl2, 0.01 mM EDTA, and
11.0 mM glucose, pH 7.4 at 37 °C. After removal of fat and con-
nective tissue, the vessel was cut into 2-mm rings, and en-
dothelium was removed to exclude the inﬂuences of it to con-
tractile response. Each ring was suspended between stainless steel
hooks in a 5-mL organ bath containing modiﬁed Krebs buffer
maintained at 37 °C and continuously aerated with 95% O2 and 5%
CO2. One hook was connected to a force transducer (Nihon-Koh-
den, Japan) to record the isometric tension in a computer system
(PowerLab8/30; Bio Research Center Co., Ltd., Japan). The SV rings
were stretched progressively to the optimal tension (2.0 g) and
allowed to equilibrate for 1 h. The buffer was changed every
30 min. After the tension of rings had completely stabilized, they
were preconstricted with 60 mM KCl. Once maximum vasocon-
striction was reached at a plateau, the ring was washed three
times with fresh modiﬁed Krebs buffer solution. Thereafter, cu-
mulative concentration-response curves to 5-HT (Sigma-Aldrich
Co.) or AngII (Sigma-Aldrich Co.) over concentration ranges of
1 nM to 10 μM were constructed. Finally, the ring was washed
three times, and the contraction in response to a second exposure
to 60 mM KCl was recorded as the control contraction. The con-
tractile reactivity of vein rings was evaluated using the percentage
of the second KCl-induced vasoconstriction as 100%.
2.2. Western blot analysis of the AT1R and 5-HT2A receptor inmembrane fractions
Following the contractile studies, the SV rings were ﬂash frozen
in liquid nitrogen and stored at 80 °C for Western blot analysis.
Frozen SV rings were crushed with manual mill SK-200 (Tokken,
inc.) and suspended in transmembrane protein extraction buffer 1
(ProteoExtract Transmembrane Protein Extraction Kit; Calbio-
chem-Novabiochem). Preparation for the membrane fractions and
Western blot analysis was performed as described previously [11].
Equal amounts of protein (5.5 μg per lane) were separated by SDS-
10% polyacrylamide gel electrophoresis and transferred onto a
polyvinylidene diﬂuoride membrane Hybond-P (GE Healthcare
Japan). The membrane was preincubated with 1% skim milk in
Tween-Tris-buffered saline (10 mM Tris–HCl [pH 7.4], 150 mM
NaCl, and 0.1% Tween-20) and reacted with rabbit anti-5-HT2A
receptor (1:2000, Santa Cruz Biotechnology), rabbit anti-β-actin
(1:2000, Cell Signaling Technology) or mouse anti-AT1R (1:1000,
abcam) overnight at 4 °C in Immuno-enhancer Reagent A (Wako).
The immunoreactive bands were reacted with horseradish per-
oxidase-conjugated anti-rabbit or anti-mouse antibodies in Im-
muno-enhancer Reagent B (Wako), visualized using the Immuno-
Star enhanced chemiluminescent detection system (Wako), and
quantiﬁed using a luminoimage LAS-4000 analyzer (GE Healthcare
Japan). Protein levels of 5-HT2A receptor and AT1R were normal-
ized by the level of β-actin.
2.3. Ethics
The Ethics Committees at both Miyazaki Prefectural Nobeoka
Hospital and Kyusyu University of Health and Welfare approved
this study, with acceptance number 09-004 (study using human
saphenous vein). All patients provided written consent to parti-
cipate in the study. These experiments were conducted in ac-
cordance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for Experiments Involving Humans.
2.4. Statistical analysis
All the data were averaged for each patients. Thus, the numbers
of subject indicated in ﬁgures are the number of patients. Statis-
tical comparisons of mean value of 5-HT- or AngII-induced vaso-
constriction were made using two-way analysis of variance (AN-
OVA). If signiﬁcant differences in vasoconstriction between the DM
and non-DM groups were found, the rank-sum test of the in-
creasing effect of DM on the vasoconstriction induced by AngII or
5-HT was carried out using the Mann-Whitney U test. Statistical
comparisons of 5-HT2A receptor and AT1R in the membrane frac-
tion of the SV smooth muscle were made using Welch's t-test. The
data are presented as mean7standard error of the mean (SEM).
Signiﬁcance was assumed at Po0.05. Statistical analyses were
performed using SPSS 21.0 J for Windows.3. Results
We examined the 5-HT- or AngII- induced constriction of iso-
lated human endothelium-denuded SVs. The cumulative admin-
istration of 5-HT (1 nM–10 μM) induced the constriction of the SV
in a concentration-dependent manner, however, the responses did
not reach a plateau at less than 10 nM 5-HT in either the DM group
(n¼9) or the non-DM group (n¼9) (Fig. 1A). Two-way ANOVA
revealed that the 5-HT- induced vasoconstriction in the DM group
was signiﬁcantly greater than that in the non-DM group
(P¼0.011). The cumulative administration of AngII (1 nM–10 μM)
induced the constriction of the SV in a concentration-dependent
manner, and the responses reached a plateau at 300–1000 nM
Fig. 1. (A) The contractile reactivity to 5-HT (A) of endothelium-denuded SVs harvested from non-DM (open circles, n¼9) and DM patients (closed circles, n¼9). The
cumulative addition of 5-HT (1 nM to 10 μM) caused SV constriction in a concentration-dependent manner in non-DM and DM groups. (B) The contractile reactivity to AngII
of endothelium-denuded SVs harvested from non-DM (open circles, n¼19) and DM patients (closed circles, n¼8). The cumulative addition of AngII (1 nM to 10 μM) caused
SV constriction in a concentration-dependent manner in the non-DM and DM groups. The data are expressed as mean7SEM. The contractile reactivity of SV to 5-HT or AngII
were evaluated as the percentage of 60 mM KCl-induced vasoconstriction as the control in each SV ring. *Po0.05 compared with the non-DM group.
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(Fig. 1B). The maximal constrictive degree was approximately 80%
of 60 mM KCl-induced constriction in the DM group, but no more
than 20% of 60 mM KCl-induced constriction in the non-DM group.
Two-way ANOVA revealed that the AngII-induced vasoconstriction
in the DM group was signiﬁcantly greater than that in the non-DM
group (Po0.0005).
To show the effect of DM on 5-HT- or AngII-induced vasocon-
striction, we determined the increasing rate by dividing the value
of contractile ligand-induced vasoconstriction at each concentra-
tion in the DM group by that at the same concentration in the non-
DM group (Table). A rank-sum test revealed that the increasing
rates of vasoconstriction elicited by AngII in the DM group to those
in the non-DM group were signiﬁcantly greater than those of va-
soconstriction elicited by 5-HT. (Po0.005).Table 1.
To clarify the reason why the constrictive responses of the SV,
especially to AngII, were signiﬁcantly enhanced in the DM group,
we determined the protein levels of 5-HT2A receptor and AT1R in
the membrane fraction prepared from the SVs harvested from the
DM or non-DM patients. Fig. 2 shows the relative amounts of re-
ceptors/β-actin quantiﬁed using a bioimage analyzer. The level of
AT1R in the membrane fraction of the DM group was signiﬁcantly
higher than that of the non-DM group (P¼0.03). The level of
5-HT2A receptor in the membrane fraction did not differ between
the DM and non-DM groups.Table 1
The increasing rates of vasoconstriction found in the DM group.
Ligand concentration (M) 1.0108 3.0108 1.010
5-HT 2.94 1.66 1.43
AngII 3.96 3.20 3.29
Indicated numerical numbers are calculated as dividing value of 5-HT- or AngII-induce
centration in the non-DM group.4. Discussion
We found that the 5-HT-induced constriction of isolated hu-
man endothelium-denuded SVs was signiﬁcantly augmented in
the DM group compared with the non-DM group, which was
consistent with our previous report [4]. The AngII-induced con-
striction of SVs was also signiﬁcantly augmented in the DM group
than in the non-DM group. Especially in the non-DM group, AngII-
induced maximal vasoconstriction was markedly lower than the
5-HT-induced one. Meanwhile, the increasing rates of AngII-in-
duced vasoconstriction in the DM group to the non-DM group
were signiﬁcantly greater than those of 5-HT-induced vasocon-
striction. These prominent differences shown between the DM and
non-DM groups, in spite of the broad grouping, were unexpected.
It has been reported that insulin resistance, a well-known risk
factor for type 2 DM, upregulates the RAAS [8,9]. Taken together,
we demonstrated, for the ﬁrst time, that not only 5-HT but also
AngII is a potent inducer of SV graft spasm in patients with DM.
Furthermore, protein level of AT1R in the membrane fraction of
human SV smooth muscle cells from DM patients was signiﬁcantly
increased as compared with that in non-DM patients, but not the
protein level of 5-HT2A receptors. These results suggest that the
mechanism for hyperreactivity to AngII in the human SV from DM
patients is due to, at least in part, the increase in the amount of
AT1R on the membrane of SV smooth muscle cells.
The incidence of DM is increasing globally, and cardiovascular
complications are the most common causes of mortality and
morbidity among DM patients [13]. Alternations in vascular7 3.0107 1.0106 3.0106 1.0105
1.21 1.26 1.24 1.29
3.14 3.12 3.08 3.46
d vasoconstriction at each concentration in the DM group by those at same con-
Fig. 2. Protein levels of (A) 5-HT2A receptor and (B) AT1R, normalized by the β-
actin, in the isolated membrane fraction of SV smooth muscle harvested from DM
(n¼6) or non-DM patients (n¼6). The data are expressed as mean7SEM. *Po0.05
compared with the non-DM group. (C) Western blots of 5-HT2A receptor, AT1R and
β-actin.
Fig. 3. Additional hypothesis on the mechanisms of diabetic SV smooth muscle
hyperreactivity as described previously (Biochem Biophys Res Commun, 412, 323–
327, 2011). PLC, phospholipase C; PKCδ, protein kinase Cδ; CaM, calmodulin; MLCK,
Ca2þ-CaM-dependent myosin light chain kinase; MLC20, 20-kDa regulatory myo-
sin light chain; PP1c, a catalytic subunit of type 1 protein phosphatase; M20, 20-
kDa non-catalytic subunit of MLCP; MYPT1, myosin phosphatase target subunit 1 of
MLCP; RhoGEF, GDP-GTP exchange factor of RhoA. Under DM conditions the pro-
tein level of AT1R in the membrane fraction is increased. Thus, the hyperreactivity
to AngII is due to not only the qualitative and quantitative deterioration of MLCP
but also the protein level of membrane AT1R increase.
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[14]. Vascular reactivity under DM conditions has been the subject
of many studies. Endothelial dysfunction among DM patients has
been well-documented and recognized as an important factor
leading to decreased vasodilatation and increased vasoconstriction
[15]. By contrast, the dysfunction of vascular smooth muscle in DM
patients is less clear and remains to be fully explored [14,16,17].
DM is also a well-established risk factor for early and late adverse
outcomes after CABG. The SV remains the most widely used con-
duit in CABG, although it has shorter patency than arterial con-
duits [18]. One of the most serious problems in CABG is bypass
graft spasm, which can lead to premature occlusion and increased
severe adverse complications [4,5]. As shown in Fig. 1A, the low
concentration of 5-HT-induced vasoconstriction (less than
100 nM) in the endothelium-denuded human SV was signiﬁcantly
augmented in the DM group than in the non-DM group, in a si-
milar manner to that observed in our previous report [7]. Inaddition, the vasoconstrictive hyperreactivity to 5-HT persisted
even with stimulation by a high concentration of 5-HT (more than
100 nM).
5-HT2A receptors are expressed on the cell membrane of the
human SV and contribute to 5-HT-induced vasoconstriction
[19,20]. At the grafted area, platelets are susceptible to activation
because endothelial cells entirely break off from the vascular wall
of the grafted vessels during the CABG process [22]. Activated
platelets release several chemical mediators including 5-HT. The
platelet-released 5-HT may induce vasospasm of the graft medi-
ated by the 5-HT2A receptor [21]. In our present study, vasocon-
striction induced by 41 μM 5-HT was greater than that induced
by 60 mM KCl in both the DM and non-DM groups. These results
strongly suggest that 5-HT could be a potent inducer of vasospasm
after CABG. As shown in Fig. 3, vasoconstriction is controlled by
both activities of myosin light chain kinase and myosin light chain
phosphatase (MLCP). 5-HT2A receptor and AT1R are coupled to Gq,
phospholipase C, RhoA/Rho kinase, and the downstream in-
tracellular signal transduction cascade. When RhoA/ROCK path-
way is activated by Gq coupled receptors, such as 5-HT2A receptor
or AT1R, the myosin phosphatase target subunit 1 (MYPT1), a
subunit of MLCP, is phosphorylated, and the phosphorylation in-
hibits MLCP activity. We previously reported that in the resting
state of the human endothelium-denuded SV, total tissue protein
levels of 5-HT2A receptor, RhoA, ROCK1 and ROCK2 did not differ
between the DM and non-DM groups. However, the total protein
level of MYPT1 was signiﬁcantly lower in the DM group than in the
non-DM group. Furthermore, the ratio of P(Thr696)-MYPT1 to total
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DM group. These results suggest that the hyperreactivity to 5-HT
or AngII in the SV smooth muscle of patients with DM is not only
due to the enhanced phosphorylation of MLCP but also due to the
defective protein level of MLCP [7]. Similar hyperreactivity of va-
soconstriction in response to noradrenaline in the renal artery was
observed with the upregulation of Rho kinase in high glucose- and
streptozotocin-induced DM model rats [22]. This hyperreactivity
was elicited not only by the dysfunction of vascular endothelial
cells but also the degeneration of the vascular smooth muscle itself
because the augmentation of vasoconstriction was detected in
endothelium-denuded, as well as intact arteries.
It has been reported that insulin resistance, the main defects in
type 2 DM, upregulates the RAAS [8,9]. In the present study, AngII
caused the vasoconstriction of endothelium-denuded SV in a
concentration-dependent manner (Fig. 1B). The AngII-induced
maximal tension of the SV in the DM group was approximately
80% of that induced by 60 mM KCl. On the other hand, the AngII-
induced maximal tension of the SV in the non-DM group was
approximately 20% of that induced by 60 mM KCl. These results
suggest that AngII is also a potent inducer of graft spasm after
CABG in DM patients but not in non-DM patients. The increasing
rates of AngII-induced vasoconstriction in the DM group to the
non-DM group were signiﬁcantly greater than those of 5-HT-in-
duced vasoconstriction (Table). This augmentation of vasocon-
strictive hyperreactivity to AngII can be partially explained by the
enhanced RhoA/ROCK pathway and the defective protein level of
MLCP, because the AT1R is coupled with Gq/11 and G12/13, similar to
the 5-HT2A receptor [7]. However, it still not clear why there is a
difference between the hyperreactivity to 5-HT and AngII induced
by DM in the SV vasoconstrictive responses. Hence, we examined
the protein level of 5-HT2A receptor and AT1R in the membrane
fraction of SV smooth muscle harvested from DM or non-DM pa-
tients. The membrane AT1R level in the DM group was signiﬁcantly
higher than that in the non-DM group (Fig. 2). On the other hand,
the membrane level of 5-HT2A receptor in the DM group was
comparable with that in the non-DM group. These results suggest
that the hyperreactivity to AngII of the human SV from DM pa-
tients is due to the increase in the membrane AT1R localization, in
addition to the quantitative and qualitative degradation of MLCP
(Fig. 3).
The use of angiotensin converting enzyme inhibitors (ACEI) or
angiotensin receptor blockers (ARB) is particularly common
among patients with hypertension. In a Japanese hospital, ap-
proximately half of patients undergoing CABG were administered
these angiotensin system inhibitors. However, the effect of ACEI/
ARB therapy on the clinical outcomes of patients undergoing CABG
is still controversial. A prospective cohort study indicated that
ACEI treatment after CABG was associated with improved in-
hospital outcomes [23]. By contrast, another clinical trial showed
that routine early initiation of quinapril, an ACEI, did not appear to
improve the clinical outcome 3 years after CABG among patients at
low risk of cardiovascular events [24]. In the report that showed
the improvement effect of ACEI on in-hospital outcomes [23], the
rate of DM patients in ACEI-administered and non-administered
groups were 37.6% and 25.0%, respectively (Po0.05). However, in
the report which did not show an improvement in clinical out-
comes [24], the rate of DM patients in ACEI-administered and non-
administered group were 9.5% and 10.4%, respectively (P¼NS).
Based on our present study, the controversial effect of ACEI, as
reported previously, may depend on the ratio of patients with DM
in the research subjects.
In conclusion, DM is associated with a high risk of SV spasm
early after CABG due to hyperreactivity to vasocontractile ligands.
In particular, AngII plays important roles in the pathogenesis of SV
spasm in DM patients, but not in non-DM patients, early afterCABG, which is often accompanied by increasing RAAS activity.
Thus, the use of ACEI or ARB in patients undergoing CABG, parti-
cularly among DM patients, undoubtedly contributes to the pre-
vention of SV graft spasm, aside from their established beneﬁts
such as antihypertensive and cardio-protective effects.Acknowledgements
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